Literature DB >> 17063374

Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations.

S Alves1, M Mangas, M J Prata, G Ribeiro, L Lopes, H Ribeiro, J Pinto-Basto, M Reis Lima, L Lacerda.   

Abstract

Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal storage disease caused by a defect in the iduronate-2-sulfatase gene (IDS). Alternative splicing of the IDS gene can occur and the underlying regulatory mechanism may be rather complex. Nevertheless, little information is available on the role of variations at the IDS locus in the splicing process. Here we report that splice mutations at the IDS locus are an important source of MPS II pathogenicity, accounting for almost 56% of Portuguese cases. Among 16 unrelated Portuguese MPS II patients, 15 different mutations were identified: six intronic splice mutations (c.104-2AG, c.241-2A>G, c.241-1G>A, c.418+1G>A, c.880-8AG and c.1181-1G>C); two exonic splice mutations (c.1006G>lC and c.1122C>T); five missense mutations (D269V, D69V, D148N, R88C and P86L); one nonsense mutation (Q465Ter); one total IDS gene deletion; and one rearrangement involving a IDS gene inversion. Furthermore, nine of the 15 detected mutations affected the usual splicing pattern at the locus. Some of them are responsible for dramatic changes in the splicing mechanism. For example, the substitution mutation, c.418+1G>A, revealed the presence of an exonic sequence inside intron 3. Our study provides evidence that the IDS locus is prone to splicing mutations and that such susceptibility is particularly high in exon 3 and neighbouring regions. Consequently, mutation screening of the IDS gene cannot be restricted to gDNA examination. Unless cDNA analysis is also conducted, misclassifications as silent or missense mutations can be produced and even uncharacteristic splice-site mutations can be misinterpreted as classic splicing defects that may generate severe, unconventional splicing alterations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063374     DOI: 10.1007/s10545-006-0403-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

Review 1.  Pre-mRNA splicing and human disease.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

Review 2.  Understanding alternative splicing: towards a cellular code.

Authors:  Arianne J Matlin; Francis Clark; Christopher W J Smith
Journal:  Nat Rev Mol Cell Biol       Date:  2005-05       Impact factor: 94.444

3.  Novel type of genetic rearrangement in the iduronate-2-sulfatase (IDS) gene involving deletion, duplications, and inversions.

Authors:  S Karsten; E Voskoboeva; X Krasnopolskaja; M L Bondeson
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  Mucopolysaccharidosis type II--genotype/phenotype aspects.

Authors:  R Froissart; I Moreira da Silva; N Guffon; D Bozon; I Maire
Journal:  Acta Paediatr Suppl       Date:  2002

5.  Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.

Authors:  Stefan Aretz; Siegfried Uhlhaas; Yuli Sun; Constanze Pagenstecher; Elisabeth Mangold; Reiner Caspari; Gabriela Möslein; Karsten Schulmann; Peter Propping; Waltraut Friedl
Journal:  Hum Mutat       Date:  2004-11       Impact factor: 4.878

6.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.

Authors:  Gene Yeo; Christopher B Burge
Journal:  J Comput Biol       Date:  2004       Impact factor: 1.479

7.  Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: maximum entropy estimates of splice junction strengths.

Authors:  Laura Eng; Gabriela Coutinho; Shareef Nahas; Gene Yeo; Robert Tanouye; Mahnoush Babaei; Thilo Dörk; Christopher Burge; Richard A Gatti
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

8.  Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients.

Authors:  R Froissart; I Maire; G Millat; S Cudry; A M Birot; V Bonnet; O Bouton; D Bozon
Journal:  Clin Genet       Date:  1998-05       Impact factor: 4.438

9.  Silencer elements as possible inhibitors of pseudoexon splicing.

Authors:  Manuela Sironi; Giorgia Menozzi; Laura Riva; Rachele Cagliani; Giacomo P Comi; Nereo Bresolin; Roberto Giorda; Uberto Pozzoli
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

10.  Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with Mucopolysaccharidosis type II revealed by a rapid PCR-based method.

Authors:  Susanna Lualdi; Stefano Regis; Maja Di Rocco; Fabio Corsolini; Marina Stroppiano; Daniela Antuzzi; Mirella Filocamo
Journal:  Hum Mutat       Date:  2005-05       Impact factor: 4.878

View more
  13 in total

1.  Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.

Authors:  Johanna Galvis; Jannet González; Alfredo Uribe; Harvy Velasco
Journal:  JIMD Rep       Date:  2015-02-15

2.  Detailed molecular characterization of a novel IDS exonic mutation associated with multiple pseudoexon activation.

Authors:  L Grodecká; T Kováčová; M Kramárek; S Seneca; K Stouffs; C De Laet; F Majer; T Kršjaková; P Hujová; K Hrnčířová; P Souček; W Lissens; E Buratti; Tomas Freiberger
Journal:  J Mol Med (Berl)       Date:  2016-11-12       Impact factor: 4.599

Review 3.  Golgi requires a new casting in the screenplay of mucopolysaccharidosis II cytopathology.

Authors:  Kinga Molnár; Julianna Kobolák; András Dinnyés
Journal:  Biol Futur       Date:  2021-11-27

Review 4.  Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.

Authors:  S Al Sawaf; E Mayatepek; B Hoffmann
Journal:  J Inherit Metab Dis       Date:  2008-07-13       Impact factor: 4.982

5.  Transposable elements in disease-associated cryptic exons.

Authors:  Igor Vorechovsky
Journal:  Hum Genet       Date:  2009-10-10       Impact factor: 4.132

6.  Molecular analysis of the iduronate-2-sulfatase gene in Thai patients with Hunter syndrome.

Authors:  S Keeratichamroen; J R Ketudat Cairns; D Wattanasirichaigoon; P Wasant; L Ngiwsara; P Suwannarat; S Pangkanon; J Kuptanon; P Tanpaiboon; T Rujirawat; S Liammongkolkul; J Svasti
Journal:  J Inherit Metab Dis       Date:  2008-05-20       Impact factor: 4.982

7.  A new mutation (1062 del 16) of iduronate-2-sulfatase gene from a Chinese patient with Hunter syndrome.

Authors:  Yi-bin Guo; Jing-xin Pan; Ya-xian Meng
Journal:  J Zhejiang Univ Sci B       Date:  2007-08       Impact factor: 3.066

8.  Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G>A (p.Gln293Gln) synonymous variation in a female create exonic splicing.

Authors:  Huiwen Zhang; Jing Li; Xinshun Zhang; Yu Wang; Wenjuan Qiu; Jun Ye; Lianshu Han; Xiaolan Gao; Xuefan Gu
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

9.  Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy.

Authors:  Gustavo M Viana; Nathália O de Lima; Rosely Cavaleiro; Erik Alves; Isabel C N Souza; Raimunda Feio; Sandra Leistner-Segal; Ida Schwartz; Roberto Giugliani; Luiz C Santana da Silva
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

Review 10.  Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana Matos; Sandra Alves
Journal:  Diseases       Date:  2016-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.